Phase II intergroup trial of alisertib in relapsed and refractory peripheral T-cell lymphoma and transformed Mycosis fungoides: SWOG 1108

Journal of Clinical Oncology

Volumn 33, Issue 21, 2015, Pages 2399-2404

  Barr, Paul M ^a   Li, Hongli ^c   Spier, Catherine ^d   Mahadevan, Daruka ^e   LeBlanc, Michael ^c   Ul Haq, Mansoor ^e   Huber, Bryan D ^e   Flowers, Christopher R ^f   Wagner Johnston, Nina D ^g   Horwitz, Steven M ^b   Fisher, Richard I ^h   Cheson, Bruce D ⁱ   Smith, Sonali M ^j   Kahl, Brad S ^k   Bartlett, Nancy L ^g   Friedberg, Jonathan W ^a  

^a UNIVERSITY OF ROCHESTER   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^c SWOG Statistical Office ^*  (United States)

^d UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

^e UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^f EMORY UNIVERSITY   (United States)

^g WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^h TEMPLE UNIVERSITY   (United States)

ⁱ GEORGETOWN UNIVERSITY HOSPITAL   (United States)

^j UNIVERSITY OF CHICAGO   (United States)

^k UNIVERSITY OF WISCONSIN MADISON   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALISERTIB; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; AURORA B KINASE; BILIRUBIN; CREATININE; MYC PROTEIN; NOTCH1 RECEPTOR; PHOSPHATIDYLINOSITOL 3 KINASE GAMMA; PROTEIN BCL 2; ANTINEOPLASTIC AGENT; AZEPINE DERIVATIVE; CYTOKINE; PYRIMIDINE DERIVATIVE; TUMOR MARKER;

ABDOMINAL PAIN; ADULT; AGED; ALOPECIA; ANEMIA; ANGIOIMMUNOBLASTIC T CELL LYMPHOMA; ANOREXIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BACKACHE; BILIRUBIN BLOOD LEVEL; CANCER PATIENT; CD4 LYMPHOCYTE COUNT; CREATININE BLOOD LEVEL; DIARRHEA; DRUG ERUPTION; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FEVER; GASTROINTESTINAL HEMORRHAGE; HUMAN; HYPERCALCEMIA; HYPERGLYCEMIA; HYPONATREMIA; HYPOTENSION; LARGE CELL LYMPHOMA; LEUKOCYTOSIS; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; MYCOSIS FUNGOIDES; NEUTROPENIA; NK T CELL LYMPHOMA; PAIN; PERIPHERAL T CELL LYMPHOMA; PHASE 2 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; SEPSIS; SIDE EFFECT; SKIN INFECTION; T CELL LEUKEMIA; THROMBOCYTOPENIA; TOXIC EPIDERMAL NECROLYSIS; TREATMENT RESPONSE; CLINICAL TRIAL; DRUG ADMINISTRATION; LYMPHOMA, T-CELL, PERIPHERAL; MIDDLE AGED; PATHOLOGY; SURVIVAL RATE; TREATMENT OUTCOME; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; AZEPINES; BIOMARKERS, TUMOR; CYTOKINES; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; LYMPHOMA, T-CELL, PERIPHERAL; MALE; MIDDLE AGED; MYCOSIS FUNGOIDES; PYRIMIDINES; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 84940482034     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2014.60.6327     Document Type: Article

References (28)

1. Mak V, Hamm J, Chhanabhai M, et al: Survival of patients with peripheral T-cell lymphoma after first relapse or progression: Spectrum of disease and rare long-term survivors. J Clin Oncol 31:1970-1976, 2013
2. Smith SM, Burns LJ, van Besien K, et al: Hematopoietic cell transplantation for systemic mature T-cell non-Hodgkin lymphoma. J Clin Oncol 31:3100-3109, 2013
3. Yakushijin Y, Hamada M, Yasukawa M: The expression of the aurora-A gene and its significance with tumorgenesis in non-Hodgkin's lymphoma. Leuk Lymphoma 45:1741-1746, 2004
4. Mahadevan D, Spier C, Della Croce K, et al: Transcript profiling in peripheral T-cell lymphoma, not otherwise specified, and diffuse large B-cell lymphoma identifies distinct tumor profile signatures. Mol Cancer Ther 4:1867-1879, 2005
5. Manfredi MG, Ecsedy JA, Chakravarty A, et al: Characterization of alisertib (MLN8237), an investigational small-molecule inhibitor of aurora A kinase using novel in vivo pharmacodynamic assays. Clin Cancer Res 17:7614-7624, 2011
6. Palani S, Patel M, Huck J, et al: Preclinical pharmacokinetic/pharmacodynamic/efficacy relationships for alisertib, an investigational small-molecule inhibitor of Aurora A kinase. Cancer Chemother Pharmacol 72:1255-1264, 2013
7. Cervantes A, Elez E, Roda D, et al: Phase I pharmacokinetic/pharmacodynamic study of MLN8237, an investigational, oral, selective aurora a kinase inhibitor, in patients with advanced solid tumors. Clin Cancer Res 18:4764-4774, 2012
8. Dees EC, Cohen RB, von Mehren M, et al: Phase I study of aurora A kinase inhibitor MLN8237 in advanced solid tumors: Safety, pharmacokinetics, and bioavailability of two oral formulations. Clin Cancer Res 18:4775-4784, 2012
9. Friedberg JW, Mahadevan D, Cebula E, et al: Phase II study of alisertib, a selective Aurora A kinase inhibitor, in relapsed and refractory aggressive B- and T-cell non-Hodgkin lymphomas. J Clin Oncol 32:44-50, 2014
10. Swerdlow SH, Campo E, Harris NL, et al: WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues (ed 4). Lyon, France, International Agency for Research on Cancer, 2008
11. Cheson BD, Pfistner B, Juweid ME, et al: Revised response criteria for malignant lymphoma. J Clin Oncol 25:579-586, 2007
12. Coiffier B, Pro B, Prince HM, et al: Results from a pivotal, open-label, phase II study of romidepsin in relapsed or refractory peripheral T-cell lymphoma after prior systemic therapy. J Clin Oncol 30:631-636, 2012
13. Horwitz SM, Advani RH, Bartlett NL, et al: Objective responses in relapsed T-cell lymphomas with single-agent brentuximab vedotin. Blood 123: 3095-3100, 2014
14. O'Connor OA, Masszi T, Savage KJ, et al: Belinostat, a novel pan-histone deacetylase inhibitor (HDACi), in relapsed or refractory peripheral T-cell lymphoma (R/R PTCL): Results from the BELIEF trial. J Clin Oncol 31:519s, 2013 (abstr 8507)
15. O'Connor OA, Pro B, Pinter-Brown L, et al: Pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma: Results from the pivotal PROPEL study. J Clin Oncol 29:1182-1189, 2011
16. Piekarz RL, Frye R, Prince HM, et al: Phase 2 trial of romidepsin in patients with peripheral T-cell lymphoma. Blood 117:5827-5834, 2011
17. Pro B, Advani R, Brice P, et al: Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: Results of a phase II study. J Clin Oncol 30:2190-2196, 2012
18. Kelly KR, Shea TC, Goy A, et al: Phase I study of MLN8237-investigational Aurora A kinase inhibitor-in relapsed/refractory multiple myeloma, non-Hodgkin lymphoma and chronic lymphocytic leukemia. Invest New Drugs 32:489-499, 2014
19. Hilton JF, Shapiro GI: Aurora kinase inhibition as an anticancer strategy. J Clin Oncol 32:57-59, 2014
20. Qi W, Spier C, Liu X, et al: Alisertib (MLN8237) an investigational agent suppresses Aurora A and B activity, inhibits proliferation, promotes endoreduplication and induces apoptosis in T-NHL cell lines supporting its importance in PTCL treatment. Leuk Res 37:434-439, 2013
21. den Hollander J, Rimpi S, Doherty JR, et al: Aurora kinases A and B are up-regulated by MYC and are essential for maintenance of the malignant state. Blood 116:1498-1505, 2010
22. Yang D, Liu H, Goga A, et al: Therapeutic potential of a synthetic lethal interaction between the MYC proto-oncogene and inhibition of aurora-B kinase. Proc Natl Acad Sci U S A 107:13836-13841, 2010
23. Wang XX, Liu R, Jin SQ, et al: Overexpression of Aurora-A kinase promotes tumor cell proliferation and inhibits apoptosis in esophageal squamous cell carcinoma cell line. Cell Res 16:356-366, 2006
24. Yao JE, Yan M, Guan Z, et al: Aurora-A down-regulates IkappaBalpha via Akt activation and interacts with insulin-like growth factor-1 induced phosphatidylinositol 3-kinase pathway for cancer cell survival. Mol Cancer 8:95, 2009
25. Liu X, Shi Y, Woods KW, et al: Akt inhibitor a-443654 interferes with mitotic progression by regulating aurora a kinase expression. Neoplasia 10:828-837, 2008
26. Mahadevan D, Morales C, Huber BD, et al: Novel targeted combination therapies for peripheral T-cell lymphoma. Presented at the 56th ASH Annual Meeting and Exposition, San Francisco, CA, December 6-9, 2014
27. Zullo K, Guo Y, Cooke L, et al: The investigational aurora A kinase inhibitor alisertib exhibits broad activity in preclinical models of T-cell lymphoma and is highly synergistic with romidepsin. Presented at the 56th ASH Annual Meeting and Exposition, San Francisco, CA, December 6-9, 2014
28. Kretzner L, Scuto A, Dino PM, et al: Combining histone deacetylase inhibitor vorinostat with aurora kinase inhibitors enhances lymphoma cell killing with repression of c-MYC, hTERT, and microRNA levels. Cancer Res 71:3912-3920, 2011